1. Home
  2. IPGP vs CELC Comparison

IPGP vs CELC Comparison

Compare IPGP & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IPG Photonics Corporation

IPGP

IPG Photonics Corporation

HOLD

Current Price

$72.48

Market Cap

3.5B

Sector

Technology

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$100.84

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IPGP
CELC
Founded
1990
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.1B
IPO Year
2006
2017

Fundamental Metrics

Financial Performance
Metric
IPGP
CELC
Price
$72.48
$100.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
8
Target Price
$86.60
$100.13
AVG Volume (30 Days)
279.9K
883.6K
Earning Date
02-10-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.60
N/A
Revenue
$963,643,000.00
N/A
Revenue This Year
$1.84
N/A
Revenue Next Year
$6.52
N/A
P/E Ratio
$120.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$48.59
$7.58
52 Week High
$92.21
$112.64

Technical Indicators

Market Signals
Indicator
IPGP
CELC
Relative Strength Index (RSI) 34.43 54.64
Support Level $73.89 $98.76
Resistance Level $75.75 $103.09
Average True Range (ATR) 2.38 4.06
MACD -0.48 -1.18
Stochastic Oscillator 3.35 17.60

Price Performance

Historical Comparison
IPGP
CELC

About IPGP IPG Photonics Corporation

IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, fiber amplifiers, and diode lasers, which are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company operates in one segment which involves the design, development, production and distribution of fiber lasers, laser and non-laser systems, fiber amplifiers, and related optical components. A large majority of the firm's revenue is derived from materials processing applications for fiber lasers, including cutting and welding, marking and engraving, and micro-processing. The company generates a majority of its revenue from North America and also has its presence in China, Japan, Germany, and other markets.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: